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The survival of mature peripheral lymphocytes 
is controlled by their immune receptors. In cas-
cades of molecular events, extracellular signals 
are transmitted through immune receptors to 
transcription factors that orchestrate the expres-
sion of batteries of genes, and thus such funda-
mental processes as the activation, proliferation, 
and elimination of lymphoid cells. For rest-
ing peripheral B lymphocytes, “tonic” B cell   
receptor (BCR) signals have been described as 
essential for survival. Ablation of BCR surface 
expression or inhibition of BCR signaling led 
to the death of resting mature B cells within   
3–6 d (Lam et al., 1997; Kraus et al., 2004). 
However, mature B cells lacking a BCR could 
be rescued by the ectopic expression of a con-
stitutive active version of P110, a catalytic 
subunit of PI3 kinase. These and further find-
ings indicated the PI3 kinase–protein kinase B 
(Akt) signaling cascade as a signaling pathway 
that supports the survival of resting mature B 
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By studying mice in which the Nfatc1 gene was inactivated in bone marrow, spleen, or germi-
nal center B cells, we show that NFATc1 supports the proliferation and suppresses the  
activation-induced cell death of splenic B cells upon B cell receptor (BCR) stimulation. BCR 
triggering leads to expression of NFATc1/A, a short isoform of NFATc1, in splenic B cells. 
NFATc1 ablation impaired Ig class switch to IgG3 induced by T cell–independent type II 
antigens, as well as IgG3+ plasmablast formation. Mice bearing NFATc1/ B cells harbor 
twofold more interleukin 10–producing B cells. NFATc1/ B cells suppress the synthesis of 
interferon- by T cells in vitro, and these mice exhibit a mild clinical course of experimental 
autoimmune encephalomyelitis. In large part, the defective functions of NFATc1/ B cells 
are caused by decreased BCR-induced Ca2+ flux and calcineurin (Cn) activation. By affecting 
CD22, Rcan1, CnA, and NFATc1/A expression, NFATc1 controls the Ca2+-dependent  
Cn–NFAT signaling network and, thereby, the fate of splenic B cells upon BCR stimulation.
© 2011 Bhattacharyya et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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N-terminal peptide, designated as -peptide, which differs 
markedly from that in NFATc2 and other NFATc proteins, 
including the NFATc1/ isoforms (Serfling et al., 2006). 
Although the functional relevance of these protein domains 
remains to be shown in detail, it is very likely that along with 
its high expression level, NFATc1/A exerts specific func-
tions in T cell and B cell physiology.
NFAT factors were originally described as regulators of 
cytokine genes in T cells, such as of Il2, Il3, Il4, Il5, Ifng, and 
Tnf genes (Serfling et al., 2000; Hogan et al., 2003; Macian, 
2005), but they also orchestrate the expression of numerous 
other genes in other cells, including B cells. However, apart 
from a study on the inactivation of Cn B1 subunit (Winslow 
et al., 2006), which affects all NFATc members and probably 
more downstream effectors, there is only a restricted number of 
comprehensive analyses on NFAT function in B cells. Investi-
gations of B cell differentiation in mice bearing NFATc1/ 
lymphocytes upon reconstitution of RAG-deficient mice with 
Nfatc1/ fetal liver cells indicated a crucial role for NFATc1 
in the development of peritoneal B1a cells (Berland and 
Wortis, 2003). In mice created by complementation of RAG/ 
blastocysts with Nfatc1/ embryonic stem cells, a strong de-
crease in -IgM–mediated proliferation of NFATc1/ B cells 
was observed (Yoshida et al., 1998).
By using mice in which the Nfatc1 gene was inactivated in 
BM, spleen, or germinal center (GC) B cells, we show that 
NFATc1 controls the fate of splenic B cells upon BCR stim-
ulation. NFATc1 inactivation impaired BCR-mediated pro-
liferation and facilitated activation-induced cell death (AICD). 
Although, apart from the loss of peritoneal B1a cells, NFATc1 
ablation did not markedly affect B cell differentiation in BM 
and periphery, it resulted in a strong decrease of Ig class switch 
to IgG3 upon immunization with T cell–independent type II 
antigens and IgG3+ plasmablast formation. NFATc1 ablation 
also resulted in a decreased capacity of NFATc1/ B cells to 
stimulate T cells to proliferate and to secrete IL-2 and IFN- 
in vitro. This is caused in part by an increase in IL-10–producing 
CD1dhighCD5+ B cells, which might also contribute to the 
mild clinical course of experimental autoimmune encephalo-
myelitis (EAE) in mice bearing NFATc1/ B cells in vivo. 
Several of these defects seem to depend on intracellular Ca2+ 
levels, which were found to be decreased in NFATc1/ splenic 
B cells. In this study, we show that, in addition to NFATc1/
A induction, NFATc1 regulates the expression and activity 
of further members of the Ca2+-dependent Cn network, such 
as CD22, Rcan1, CnA, and NFATc2, and thus affects the sur-
vival and function of peripheral B cells.
RESULTS
BCR triggering of naive splenic B cells leads to strong 
induction of NFATc1/A
Stimulation of naive splenic B cells from 6–8-wk-old mice 
with 10 µg/ml anti-IgM antibody (-IgM; the F(ab)2 frag-
ment of anti–mouse IgM) in vitro leads to strong induction of 
NFATc1 after 24 h. A similar strong induction of NFATc1 
was  also  detected  by TPA+ionomycin  (T+I)  treatment, 
cells by tonic BCR signals in the periphery (Srinivasan et al., 
2009). Although these and other studies elucidated important 
signaling molecules for the survival of resting peripheral B cells, 
they did not address which signaling pathways control the sur-
vival and function of peripheral B cells upon BCR stimulation.
In a typical immune response, triggering of immune re-
ceptors by cognate antigens culminates in the massive clonal 
expansion of peripheral lymphocytes, followed by elimina-
tion of most of the amplified effector cells by apoptosis toward 
the end of the immune response (Strasser and Pellegrini, 2004; 
Krammer et al., 2007). Although immune reactions depend 
on numerous parameters, immune receptor signals are key de-
terminants that control the strength of an immune response 
and the onset of apoptosis, and thus the termination of the 
immune response. Triggering of BCR results in the rapid 
phosphorylation of several proximal signaling molecules, such 
as Bruton’s tyrosine kinase (Btk), phospholipase C2 (PLC-2), 
and others, by the tyrosine protein kinases Lyn and Syk. Along 
with tyrosine phosphorylated B cell adaptor proteins, such as 
SLP-65/BLNK, these molecules assemble in supramolecular 
complexes that transmit BCR signals to downstream serine/
threonine protein kinases and, finally, to transcription factors. 
By hydrolyzing phosphatidylinositols to diacylglycerol and ino-
sitol 1,4,5-triphosphate (IP3) that, in turn, binds to and stimu-
lates IP3 receptors, PLC-2 affects the release of Ca2+ from 
intracellular stores and the subsequent influx of extracellular 
Ca2+ (King and Freedman, 2009). An increase in intracellular 
Ca2+ levels leads to the activation of the Ca2+/calmodulin-
dependent Ser/Thr-specific phosphatase calcineurin (Cn; also 
designated as PP2B), which dephosphorylates and activates 
members of NFAT transcription factors by facilitating their 
nuclear translocation.
Together with NFATc2 (also designated as NFAT1), 
NFATc1 (or designated as NFAT2) belongs to the most 
prominent NFAT factors in activated lymphocytes. However, 
contrary to NFATc2, which is constitutively expressed in 
most peripheral lymphocytes, the expression of NFATc1 in 
peripheral lymphocytes is strongly induced at the transcrip-
tional level. In CD4+ T cells, the transcription of Nfatc1 
gene is induced by TCR triggering and co-stimulatory sig-
nals  (Chuvpilo  et  al.,  1999,  2002;  Nurieva  et  al.,  2007), 
whereas, as we show here, BCR triggering induces NFATc1 
expression in splenic B cells. The induction of NFATc1 ex-
pression upon immune receptor stimulation is an important 
control level of NFAT activity. The observation that NFAT 
factors have to reach a certain threshold level for the induc-
tion of the IL-2 (Il2) promoter in T cells was made nearly 
20 yr ago (Fiering et al., 1990). The induction of Nfatc1 gene 
is controlled by a switch from the constitutively active pro-
moter P2 to the inducible P1 promoter, whose activity directs 
the  predominant  synthesis  of  short  isoform  NFATc1/A 
(Chuvpilo et al., 2002). This isoform differs from other NFATc 
proteins in its short C terminus, and thus lacks a second trans-
activation domain present in longer NFATc1 isoforms (Avots 
et al., 1999) that harbor two highly conserved sumoylation 
motifs (Nayak et al., 2009). NFATc1/A contains an individual JEM VOL. 208, April 11, 2011 
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To generate mice in which the murine Nfatc1 gene was   
inactivated in B cells, Nfatc1flx/flx mice were crossed with 
mice that specifically express the cre enzyme in B cells of 
BM (mb1-cre; Hobeika et al., 2006), spleen (Cd23-cre; Kwon   
et al., 2008), or GC (Aicda-cre; Kwon et al., 2008). Crossing   
of Nfatc1flx/flx mice with the mb1-cre and Cd23-cre lines re-
sulted in the ablation of NFATc1 expression in splenic B cells 
(Fig. S1, B–D).
Flow cytometric analyses of B cell development in BM 
from WT and mb1-cre x Nfatc1flx/flx mice did not show sig-
nificant differences in the expression of B220, CD43, BP-1, 
CD24, IgM, and IgD on pro–B cells (Hardy fractions B and C; 
Hardy and Hayakawa, 2001; CD24+BP-1 and CD24+BP-1+ 
fractions in B220+CD43hi cells), pre–B cells, and immature 
and mature B cells (Hardy fractions D–F; Hardy and Hayakawa, 
2001; Fig. S2 A). Likewise, the differentiation of LN and splenic 
NFATc1/  B  cells  appeared  to  be  relatively  unaffected   
(Fig. S2 B), although only 75–80% B cells were counted in prep-
arations of whole splenic B cells from 7 mb1-cre x Nfatc1flx/flx 
mice compared with WT mice. Stains of splenic B cells for 
CD21+CD23 revealed similar ratios of follicular B cells and 
marginal zone B cells (MZBs) from WT and mb1-cre x Nfatc1flx/flx 
mice (Fig. S2 C). Also, the maturation of splenic B cells did not 
markedly differ between WT and NFATc1/ cells (Fig. S2 D). 
However,  in  agreement  with  published  data  (Berland  and 
Wortis, 2003), in peritoneal washes from mb1-cre x Nfatc1flx/flx 
mice a 5–10-fold decrease in the population of B1a cells was de-
tected. In the peritoneum of Cd23-cre x Nfatc1flx/flx mice, B1a 
cells that do not express CD23 were found in normal num-
bers (Fig. S2, E and F).
whereas a much weaker induction was observed after stimula-
tion of B cells with 10 µg/ml LPS or 2 µg/ml -CD40 (Fig. 1 A 
and Fig. S1 A). The short NFATc1 protein induced by -IgM 
reacted with an antibody raised against the NFATc1 -peptide 
and corresponds to NFATc1/A, whereas the NFATc1   
version induced by LPS did not react (Fig. 1 B). The Western 
blot data on the important role of BCR signals in NFATc1 
induction are supported by the strong induction of an Egfp 
reporter gene controlled by the Nfatc1 locus upon -IgM 
stimulation. When splenic B cells from mice bearing a BAC-
Nfatc1/Egfp transgene were stimulated by -IgM, LPS, or   
-CD40 for 24 h, a much stronger GFP induction was detected 
after -IgM than after LPS or -CD40 treatment (Fig. 1 C).
To show that BCR-mediated induction of NFATc1 is af-
fected by prototypical signaling molecules of the BCR-signaling 
pathways, we investigated the effect of -IgM stimulation on 
NFATc1 induction in splenic B cells from mice deficient for 
the protein tyrosine kinase Btk (Kerner et al., 1995; Khan et al., 
1995) or the adaptor molecule SLP-65 (Jumaa et al., 1999).   
As shown in Fig. 1 (D and E), inactivation of either Btk or 
SLP-65 led to complete loss of NFATc1 induction, indicating 
that the strong induction of NFATc1/A is mediated through 
these signaling molecules, which are known to be key com-
ponents of BCR signaling.
NFATc1 ablation suppresses the formation of peritoneal B1a 
cells, but does not interfere with B cell development in BM 
and spleen
To investigate the role of NFATc1 in B cell physiology we 
used mice bearing “floxed” exon 3 alleles of Nfatc1 (Nfatc1flx/flx). 
Figure 1.  NFATc1 induction in naive 
mouse splenic B cells. (A and B) Freshly 
prepared splenic B cells were stimulated with 
10 µg/ml -IgM or 10 µg/ml LPS for 0–48 h. 
Whole-cell protein was fractionated on 8% 
polyacrylamide gels and immunoblotted with 
either the mAb 7A6 recognizing all NFATc1 
isoforms (A) or an antibody raised against the 
N-terminal -peptide of NFATc1 (B). In lane  
1 of panel B, protein from HEK 293 cells 
transfected with an NFATc1/A expression plas-
mid was fractionated. NS, nonspecific band.  
(C) Splenic B cells from mice expressing an 
Nfatc1-Egfp reporter transgene were either 
left unstimulated or stimulated for 16 or 24 h. 
GFP fluorescence was determined by flow 
cytometry. (D and E) Splenic B cells from WT, 
Btk-deficient, or SLP-65-deficient mice were 
left unstimulated (Unst.) or were stimulated 
with LPS or -IgM for 24 h, and whole  
protein extracts were immunoblotted using 
the NFATc1-specific mAb 7A6. ERK2 and  
-actin, loading controls. In A-C, one typical 
experiment from more than three assays is 
shown; in D and E, one blot from two similar 
blots is presented.826 NFATc1 controls mouse B cell fate | Bhattacharyya et al.
chromatin immunoprecipitation (ChIP) assays using spleno-
cytes that were either left noninduced or induced with T+I 
or -IgM for 16 h. Upon immunoprecipitation with an 
NFATc1-specific antibody, we detected a marked increase in 
NFATc1 binding to the promoters of Pdcd1, Tnfsf14, and Fasl 
genes after both stimulations (Fig. 2 E). In contrast, the Spp1 
and Rcan1 promoters already showed NFATc1 binding in non-
stimulated cells, but stimulation increased their NFATc1 bind-
ing. As expected, for the Il2 promoter an increase in NFATc1 
binding was observed upon T+I stimulation but not upon   
-IgM stimulation (Fig. 2 E).
To show whether in our assays PD-1 and LIGHT might 
affect the survival of B cells, we stimulated splenic B cells from 
PD-1 and LIGHT deficient mice by -IgM. Compared with 
WT B cells, both types of B cells showed a strong reduction 
in AICD (Fig. S3 D). This indicates that three of the most 
prominent NFATc1 targets in primary B cells, the Pdcd1, Tnfs14 
and Fasl genes, code for proapoptotic proteins.
Apart from the Ccnb1/Cyclin B1 gene, among the 53 genes 
that showed a twofold and stronger increase in expression 
upon BCR stimulation in WT (compared with NFATc1/ 
B cells) we did not detect genes that directly control cell cycle 
and proliferation (Table S1).  This suggests that NFATc1 enhances 
the expression of (numerous) genes controlling proliferation 
only to moderate levels. Such view finds support in gene set 
enrichment analyses (GSEA) of microarray data in which nu-
merous gene signatures enhancing proliferation were signifi-
cantly enriched in WT B cells compared with NFATc1/  
B cells. Among those are eleven signatures that are significantly 
associated with cell cycle and proliferation (Table I), and nu-
merous cell cycle–associated genes. In addition to the Ccnb1 
gene, these include several cyclin genes, which are listed as 
signature genes in leading edge analyses (Table S3).
NFATc1 supports the proliferation of B cells by controlling 
their Ca2+ flux and Cn activity
Among the 10 genes whose expression was most strongly 
suppressed by NFATc1 in B cells are the Cd22, Fcer2a/CD23, 
and S100a4 genes, whose activity modulates (or is modulated 
by) intracellular Ca2+ levels in B cells (Fig. 3 A; Kolb et al., 1990; 
Nitschke, 2009; Matsuura et al., 2010). These findings suggest 
that NFATc1, as one of the most prominent NFATc1 targets 
(along with Rcan1; Figs. 2, C and E), controls BCR-mediated, 
store-operated Ca2+ entry, and thus the Ca2+-dependent Cn 
network, for its own induction in B cells.
Sustained Ca2+ entry is necessary for many physiological 
processes controlling lymphocyte activity, including their 
proliferation and apoptosis (Hogan et al., 2010). This is illus-
trated for splenic B cells in Fig. 3 B. Almost all cells prolif-
erated when freshly prepared splenic B cells were cultured in 
X-vivo medium, a medium rich in Ca2+, whereas in a 1:1 
mixture of X-vivo and RPMI media (the latter contains 
about one-third the amount of Ca2+ as the X-vivo medium) 
<50% of B cells were found to proliferate. Adding 10 mM 
Ca2+ to this medium restored the proliferative capacity, whereas 
inhibiting Cn by cyclosporin A (CsA), either at the start of 
Impaired BCR-induced proliferation and increased AICD  
of NFATc1/ splenic B cells
Investigations of the -IgM–mediated proliferative capacity 
of splenic NFATc1/ B cells in CFSE dilution assays and 
[3H]thymidine incorporation experiments showed a marked 
decrease in their proliferation in vitro, compared with WT   
B cells. In contrast, no differences in proliferation were observed 
between NFATc1/ and WT B cells upon LPS or -CD40 
stimulation (Fig. 2 A and Fig. S3 A). In addition, NFATc1/ 
splenic B cells showed a distinct increase in -IgM–mediated 
apoptosis. This is reflected in the relative drop of living cells 
(as shown by their SSC-FSC features; Fig. S3 B) and the in-
crease of Annexin V–positive apoptotic NFATc1/ cells com-
pared with  WT B cells (Fig. 2 B). Similar differences in survival 
between WT and NFATc1/ B cells were detected in cell 
cycle analysis by PI staining upon -IgM stimulation for   
48 h, showing a pronounced increase in hypoploid sub-G1 
cells from 20–40% (Fig. S3 C). The increase in -IgM– 
mediated AICD is a specific feature of NFATc1/ B cells 
because contrary to those, NFATc2/ B cells were resistant 
to -IgM–mediated apoptosis (Fig. 2 B), which agrees with 
the pro-apoptotic activity of NFATc2 in activated T cells, as 
previously described (Chuvpilo et al., 2002).
NFATc1 controls numerous genes that affect  
the AICD of B cells
For the identification of NFATc1 target genes that control 
the proliferation and/or AICD of B cells, we investigated 
gene expression of splenic B cells by using mouse whole- 
genome expression arrays. Freshly isolated B cells from WT 
and mb1-cre x Nfatc1flx/flx mice were either left uninduced or 
induced by -IgM for 3, 8, or 16 h. We identified 53 genes 
whose expressions were enhanced by more than twofold and 
37 genes whose expression was suppressed more than twofold by 
NFATc1 upon -IgM stimulation for 16 h (Tables S1 and S2). 
Among the enhanced “top ten” genes are the Spp1, Rcan1, 
Pdcd1, Tnfsf14, and Fasl genes that encode apoptosis regula-
tors (Fig. 2 C). The Spp1 gene encodes the multifunctional 
protein osteopontin (Hur et al., 2007); the Rcan1 gene encodes 
the Cn modulator calcipressin (Vega et al., 2003); the Pdcd1 
gene encodes PD-1 (CD279), a member of the Ig supergene 
family which is expressed on T and B cells (Keir et al., 2008); 
and the Tnfsf14 gene encodes LIGHT (CD258), a member of 
the TNF family that is a ligand of the lymphotoxin  recep-
tor (LTR) and herpes virus entry mediator (HVEM; Scheu 
et al., 2002). Although the RNA levels of all five genes were 
almost undetectable in nonstimulated B cells, the expression 
of Spp1 and Rcan1 genes was rapidly induced by -IgM 
treatment for 3 h and decreased (Spp1) or remained quite 
constant (Rcan1) afterward in NFATc1/, but not WT B 
cells. In contrast, the expression of Pdcd1, Tnfsf14, and Fasl 
genes was undetectable upon 3 h induction and increased 
strongly after 16 h of -IgM stimulation in WT but not 
NFATc1/ cells (Fig. 2 D).
To show that the Spp1, Rcan1, Pdcd1, Tnfsf14, and Fasl genes 
are genuine NFATc1 targets in splenic B cells, we performed JEM VOL. 208, April 11, 2011 
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inhibitor (Aramburu et al., 1999). The mild proliferative de-
fect of NFATc1/ B cells upon -IgM stimulation (Fig. 2 A 
and Fig. 3 B) is in line with the observation that NFATc1/ 
B cells exhibit a marked reduction in Ca2+ flux (Fig. S4 E), 
the experiment or 1 d later, blocked any proliferation of   
B cells (Fig. 3 B). A similar strong effect has been observed 
with 10 µM NCI3, a novel Cn inhibitor (Sieber et al., 2007), 
and 2.5-µM Vivit-11R (Fig. S4, A and C), a specific NFAT 
Figure 2.  NFATc1 is required for optimal proliferation and survival of splenic B cells. (A) CFSE-labeled splenic B cells from a WT and mb1-cre x 
Nfatc1flx/flx mouse were incubated for 72 h in the absence (Unstim.) or presence of 10 µg/ml LPS, 10 µg/ml -IgM, or 2 µg/ml -CD40. CFSE dilution was 
measured by flow cytometry. (B) Splenic B cells from WT, mb1-cre x Nfatc1flx/flx, and Nfatc2/ mice were incubated for 72 h; cells were stained with PI 
and Annexin V and analyzed by flow cytometry. (C) WT and mb1-cre x Nfatc1flx/flx (KO) splenic B cells were stimulated with -IgM, as indicated. Gene ex-
pression was analyzed by DNA microarray. Key at the bottom indicates the fold changes in gene expression (log2 values). (D) Induction of 10 NFATc1  
target genes by -IgM stimulation in WT and NFATc1/ splenic B cells. Error bars show ± the SEM. (E) ChIP assay showing the in vivo binding of NFATc1 
in splenocytes to the promoters of Il2, Rcan1, Spp1, Fasl, Pdcd1, and Tnfsf14 genes upon stimulation for 16 h with -IgM or T+I. Lanes 1–3, ChIP assays 
using splenocytes that were left unstimulated (-) or stimulated by T+I or -IgM for 16 h. ChIP assays were also performed using an antibody directed 
against GST protein. As input control, 1% of chromatin of all assays was used. In A and B, one typical experiment is shown from more than three assays; 
in C and D, mean values from three individual DNA microarray analyses are presented, and in E one typical ChIP assay from three assays is shown.828 NFATc1 controls mouse B cell fate | Bhattacharyya et al.
we detected markedly less NFATc2 in nuclei of NFATc1/ 
B cells than WT cells (Fig. 3 F). This suggests an impaired 
NFATc2 activation in the absence of NFATc1. In RNA levels, 
no differences were detected for NFATc2 RNA between 
WT and NFATc1/ B cells, whereas a slight decrease in 
NFATc3 RNA levels was observed for NFATc1/ B cells, 
compared with WT cells (Fig. 3 F). However, because no dis-
tinct increase in NFATc3 RNA levels was detected upon 
-IgM stimulation in WT B cells (Fig. 3 F), NFATc1 appears 
to indirectly affect Nfatc3 gene expression.
Collectively, these data indicate that NFATc1 controls Rcan1 
and CnA expression, i.e., its immediate upstream control mole-
cules, which, in a feedback loop, affect the transcriptional in-
duction of NFATc1. In addition, NFATc1 seems to also affect 
upstream BCR signals, probably through CD22 and other 
targets. A scheme of this network connecting NFATc1 with 
its upstream activators in B cells is shown in Fig. S5A.
NFATc1 affects Ig class switch by T cell–independent  
type II antigens
Interruption of BCR signaling by inactivating Btk, SLP-65, 
PLC-2, and further components of the BCR signaling 
cascade not only leads to a drastic decrease in Ca2+ flux, but 
also to defects in Ig class switching upon immunization with   
T cell–independent type II (TI-II) antigens (Kerner et al., 
1995; Khan et al., 1995; Jumaa et al., 1999; Wang et al., 2000). 
When we measured Ig levels in sera from nonimmunized WT 
mice and mice bearing NFATc1/ B cells, we did not detect 
statistically significant differences in the concentration of Ig 
classes (except IgM in Cd23-cre x Nfatc1flx/flx mice; Fig. S5 B). 
However, upon immunization with the TI-II antigen NP-Ficoll, 
we detected 10-fold lower IgG3 serum levels in Cd23-cre x 
Nfatc1flx/flx mice, compared with those from WT mice. Slight, 
but statistically significant, differences were also detected in IgM 
levels 2 wk after immunization (Fig. 4 A). Very similar results 
were obtained upon immunization of Aicda-cre x Nfatc1flx/flx 
mice that resulted in tenfold lower IgG3 serum levels compared 
in both the release of Ca2+ from intracellular stores and in 
influx of extracellular Ca2+ to 60% of level to that in WT 
cells (Fig. 3 C).
CD22 is an inhibitory co-receptor of BCR that is tran-
siently expressed on splenic B2 cells (Nitschke, 2009). Its surface 
expression is impaired by BCR stimulation (Lajaunias et al., 
2002) and, as flow cytometric assays of WT and NFATc1/ 
B cells imply, NFATc1 contributes to CD22 suppression 
(Fig. 3 D). This conclusion is supported by the DNA micro-
array data (Fig. 3 A and Table S2) and semiquantitative RT-PCR 
assays that showed higher CD22 RNA levels in NFATc1/ 
than WT B cells treated by -IgM for 16 h (Fig. 3 D). Splenic 
B cells from CD22/ mice show, on the other hand, a strong 
NFATc1/A expression in noninduced and LPS-treated B cells, 
whereas WT B cells express isoforms other than NFATc1/A 
under these conditions (Fig. 1 A and Fig. S4 F).
In addition to the Rcan1 gene, the Ppp3cb gene encoding 
the large CnA  subunit that is predominantly expressed in 
lymphocytes is a further direct NFAT target. This has been 
shown previously for cardiomyocytes (Oka et al., 2005), and 
in ChIP assays we detected the in vivo binding of NFATc1 
to the 5 region of Ppp3cb gene upon -IgM stimulation 
(Fig. 3 E, top), whereas no NFATc1 binding was found to the 
5 region of Ppp3ca gene (not depicted). In Western blots 
using an antibody recognizing CnA / proteins, a strong 
decrease in the -IgM–mediated induction of one CnA-specific 
protein was detected in protein extracts from NFATc1/ 
B cells (Fig. 3 E, middle), suggesting an important role of NFATc1 
in CnA expression and function. This conclusion is sup-
ported by the marked decrease of Cn activity in extracts from 
freshly prepared NFATc1/ B cells, compared with WT   
B cells (Fig. 3 E, bottom).
The diminished Cn activity suggests that the activation of 
other NFATc factors might also be impaired in NFATc1/ 
B cells. In immunohistochemical stainings of B cells from WT 
and mb1-cre x NFATc1flx/flx mice stimulated for 1 or 2 d with 
-IgM and -CD40 and restimulated for 30 min with T+I, 
Table I.  Gene set enrichment analysis
Pathways/ 
signatures
References Enriched in WT Enriched in Nfatc1/ 
B cells
Nominal P value FDRq value
Cell cycle Brentani et al., 2003 
Cho et al., 2001 
Whitfield et al., 2002 
Liu et al., 2004
Yes No <0.0001 <0.07
Proliferation Shaffer et al., 2002 
Rosenwald et al., 2002 
Su et al., 2004
Yes No <0.0001 <0.09
Myc targets Zeller et al., 2003 
Yu et al., 2005
Yes No <0.01 <0.08
Antiapoptosis Wu et al., 2002 Yes No ≤0.01 <0.08
Wnt signaling Kenny et al., 2005 Yes No <0.031 0.24
Gene set enrichment analysis (GSEA) of microarray data of splenic B cells from WT and mb1-cre x Nfatc1flx/flx mice stimulated for 16 h by -IgM using 81 lymphoma-
associated signatures from the signature database of the Staudt laboratory (http://lymphochip.nih.gov/signaturedb) and 1.687 curated gene sets (c2) from the Molecular 
Signatures Database (MSigDB; Subramanian et al., 2005). All references mentioned in Table I are cited in Subramanian et al., 2005.JEM VOL. 208, April 11, 2011 
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Figure 3.  NFATc1 controls Ca2+/Cn signaling in splenic B cells. (A) DNA microarray assay showing 10 genes whose expression was enhanced in  
B cells from mb1-cre x Nfatc1flx/flx mice compared with WT B cells. Mean values of 3 individual assays are shown. (B) Manipulation of Ca2+/Cn signaling by 
adding 10 mM CaCl2 or 100 ng/ml CsA to proliferation assays. Splenic B cells from WT or mb1-cre x Nfatc1flx/flx mice were stained with CFSE and treated 
with 10 µg/ml -IgM in the absence or presence of Ca2+ or CsA in X-vivo medium or 1:1 X-vivo+RPMI medium that contains less Ca2+. Numbers indicate 
the percentage of cycling cells. One typical set of more than three experiments is shown. (C) Ca2+ release and influx in B cells from WT and mb1-cre x 
Nfatc1flx/flx (KO) mice. One typical experiment from more than three assays is shown. (D) Effect of NFATc1 ablation on CD22 expression. (left) Semiquanti-
tative RT-PCR assay showing an increase in CD22 RNA in NFATc1/ splenic B cells. One typical assay from three individual assays is shown. (right) Flow 
cytometric detection of CD22 expression on WT and Cd23-cre x Nfatc1flx/flx splenic B cells left unstimulated or stimulated with LPS or -IgM for 2 h.  
Two more assays with B cells from two mice each were performed and gave similar results. (E) CnA assays. (top) ChIP assay for the binding of NFATc1 to 
the Ppp3cb and Il2 promoter in vivo. Splenocytes were left unstimulated () or stimulated with -IgM for 16 h. As indicated, either an NFATc1-specific or 
an unrelated antibody (-GST) was used. As input control, 1% of chromatin of all assays was used. (middle) Immunoblot using whole cellular protein 
from B cells and a CnA /-specific antibody. Below the blot, Ponceau red staining is shown as loading control. (bottom) Mean values of Cn activity from 
three assays are shown (P ≥ 0.05 between WT and mb1-cre x Nfatc1flx/flx cells). (F) Effect of NFATc1 ablation on NFATc2 expression. (top) Decrease in  
nuclear NFATc2 in NFATc1/ B cells. Splenic B cells were treated with -IgM and -CD40 for 24 h, and for the last 30 min, the cells were also treated 
with T+I. Splenic B cells stained with an NFATc2-specific antibody. (right) Nuclear staining of 100 cells measured by confocal microscopy is compiled. 
(bottom) Semiquantitative RT-PCR assay. Error bars show ± the SEM. 830 NFATc1 controls mouse B cell fate | Bhattacharyya et al.
Figure 4.  NFATc1 deficiency results in a defect in IgG3 class switch by the TI-type II antigen NP-Ficoll. (A) IgM and IgG3 levels in sera of WT, 
Cd23-cre, and Aicda-cre x Nfatc1flx/flx mice after immunization with the TI-type II antigen NP-Ficoll. Each symbol represents one mouse. (B) Appearance of 
circular IgG3 and IgG1 transcripts in WT and NFATc1/ splenic B cells after in vitro culture for 2 d in the presence of LPS. (C) ELISA showing a decrease in 
IgG3 production of B cells from Cd23-cre x Nfatc1flx/flx mice upon culture for 6 d. (D) Decreased IgG+ plasmablast formation of B cells from Cd23-cre x 
Nfatc1flx/flx mice upon 3 d in culture. Flow cytometry of CD19+-gated B cells. In the columns data from three assays are compiled. (E and F) Diminished JEM VOL. 208, April 11, 2011 
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with WT mice 1, 2, or 3 wk after primary injection. Again, 
the differences in IgM serum levels were smaller after 2 and 3 
wk of immunization, but statistically significant (Fig. 4 A).
These in vivo data are supported by the Ig class switch to 
IgG3 in cultured B cells. Although in cultures of splenic B cells 
circular RNA transcripts of IgG3 switch region could be 
detected in WT B cells after 2 d, no circular transcripts were 
observed in NFATc1/ B cells, whereas circular IgG1 tran-
scripts could be detected in both WT and NFATc1/ B cells 
(Fig. 4 B). Measuring of secreted IgM and IgG3 antibodies re-
vealed a decrease in IgG3 secretion of 50% compared with 
WT cells (Fig. 4 C). After culturing B cells for 5 d, the percentage 
of CD138+ IgG3+ plasmablasts generated from NFATc1/ 
cells decreased to 30% of IgG3+ WT plasmablasts (Fig. 4 D). 
This might be caused, in part, by a decrease in proliferation 
and increase in AICD. Indeed, this was found for NFATc1/ 
CD138+ plasma cells in vitro (Fig. 4, E and F).
The Ig switch to IgG3 by TI-type II antigen takes place in 
B cells expressing high levels of NFATc1. This was shown by 
measuring NFATc1, IgM, and IgG3 levels in preparations of 
splenocytes from Nfatc1-Egfp reporter mice upon immuniza-
tion with NP-Ficoll by flow cytometry. A high level of NFATc1 
expression was detected for IgM+IgG3+ B cells, whereas B 
cells expressing only IgM expressed less NFATc1 (Fig. 4 G). 
NFATc1/GFPhigh cells also expressed high levels of the GC 
markers PNA and Fas, the plasma cell marker CD138, and the 
activation marker CD69 (Fig. 4 G), indicating a close link be-
tween NFATc1 expression and Ig class switch.
TI-II antigens rapidly stimulate MZBs to produce IgM 
and IgG3, and defects in Ig class switch upon TI-II antigen 
immunization  are  often  correlated 
with a decrease or lack of MZB cells 
(Martin  and  Kearney,  2002;  Lopes-
Carvalho and Kearney, 2004). Surpris-
ingly, we did not notice a reproducible 
decrease in population of MZB cells 
in spleens of mice bearing NFATc1/ 
B cells, but defects in their function. 
When we injected TNP-Ficoll into mice and measured its 
binding to B cells, we observed a decrease in binding of TNP-
Ficoll to NFATc1/ MZB cells, compared with MZB cells 
in WT mice. This is shown in Fig. 5 A for 8–9 mo old mice, 
whereas in younger 7–8-wk-old mice a 40–60% reduction in 
TNP-Ficoll binding was observed (unpublished data). 1 h after 
i.v. injection, TNP-Ficoll formed a ring like structure in the 
marginal zone of B cell follicles, distal of IgDhigh B2 cells and 
associated with metallophilic macrophages (Fig. 5, B and C). 
Whereas in spleen from WT mice TNP-Ficoll was found 
to be evenly distributed and closely associated with IgMhigh 
MZBs, larger aggregates of antigen were detected around, but 
not associated with CD169+ macrophages and IgMhigh MZB 
cells in mice with NFATc1/ B cells (Fig. 5, C and D, white 
arrows). Similar deposits of antigen aggregates were described 
upon TNP-Ficoll immunization of mice deficient in Pyk-2, 
complement C3, or complement receptor CR1/2. All of 
these mice exhibit marked defects in MZB cells (Guinamard 
et al., 2000).
Contrary to the immunizations with TI-type II antigen, 
we did not detect remarkable differences in Ig class switch 
upon immunization with NP-KLH, a T cell–dependent (TD) 
antigen. Injections of four WT and four Cd23-cre x Nfatc1flx/flx 
mice with NP-KLH (in alum) revealed only subtle, albeit sta-
tistically significant differences in serum levels of IgG2a one 
and two wks of immunization, but no differences in IgM, 
IgG1 and IgG2b levels (Fig. S5 C). On the same hand, no dif-
ferences were detected in the affinity of IgG1 serum antibodies 
generated in WT and Cd23-cre x Nfatc1flx/flx mice (Fig. S5 D). 
This shows that in contrast to the strong effect on Ig class 
proliferation (E) and increased AICD (F) of CD138+ plasmablasts generated from B cells of Cd23-cre x Nfatc1flx/flx mice upon 3 d culture. (G) Strong Nfatc1-Egfp 
reporter gene expression in plasmablast-like B cells upon immunization of mice with NP-Ficoll. Flow cytometry of splenic B cells showing GFP and 
IgM+IgG3, PNA+FAS, CD138, or CD69 expression, respectively. In E–G, one typical experiment from three assays is shown. Error bars show ± the SEM. 
 
Figure 5.  TNP-Ficoll antigen does not 
bind to NFATc1/ MZB cells, but forms 
large aggregates in spleen. 150 µg TNP-
Ficoll was injected i.v., and 1 h later splenic  
B cells were prepared for flow cytometry (A) or 
spleens were taken for histochemical staining 
(B–D). In A, binding of antigen to MZB cells was 
determined by staining with APC-labeled  
-TNP-Ficoll. In B–D, histochemical stainings 
were performed using -TNP-Ficoll, -IgD,  
-CD169/MOMA-1, and -IgM. Typical results 
from three injection experiments are shown.832 NFATc1 controls mouse B cell fate | Bhattacharyya et al.
Several lines of evidence indicated that B cells can sup-
press immune reactions by secreting IL-10, and thereby   
affect the course of autoimmune diseases (Bouaziz et al., 2008; 
Lampropoulou et al., 2010). Compared with splenic B cells 
from WT mice, splenic B cells from Cd23-cre x Nfatc1flx/flx 
mice harbor twofold more CD19+CD5+CD1dhigh B cells that 
were described to produce IL-10 (Fig. 7 A; Matsushita et al., 
2008). Upon treatment by LPS for 24 h (and, in addition, by 
T+I for the last 8 h) in vitro, the percentage of IL-10–producing 
CD5+CD1dhigh B cells increased twofold (Fig. 7 B; note the 
lack of any IL-10 signal for splenic B cells from IL-10/ 
mice). A similar increase in the percentage of IL-10–producing 
CD138+ plasmablasts was detected upon differentiation of 
NFATc1/ splenocytes for 3 d in vitro (Fig. 7 C). Incuba-
tion with LPS, but not -IgM, led to a strong increase in 
IL-10 secretion of both WT and NFATc1/ B cells, again 
with higher IL-10 levels for NFATc1/ than for WT B cells 
(Fig. 7 D). By adding B cells from WT or Cd23-cre x NFATc-
1flx/flx mice, which were stimulated overnight with -IgM or 
LPS or left unstimulated, to allogenic T cells, NFATc1/ 
switch by TI-type II antigens, inactivation of NFATc1 in B cells 
exerts a mild, if any effect on Ig class switch by TD antigens 
in the primary response.
NFATc1 affects the regulatory capacity of B cells in vitro 
and in vivo
B cells control immune reactions by presenting antigens to   
T cells by releasing cytokines and secreting humoral antibodies. 
When  we  tested  the  effect  of  NFATc1/  C57BL/6  B 
cells on allogenic T cells from BALB/c mice in MLCs we ob-
served a stronger stimulatory activity of WT B cells than 
NFATc1/ B cells on T cell proliferation and IL-2 synthesis. 
This indicates NFATc1/ B cells as poor activators of   
T cells (Fig. 6, A and B). This conclusion found support in 
the weak stimulatory capacity of NFATc1/ B cells pre-
senting an OVA peptide (OVA323-339) to syngenic CD4+  
T cells from OTII mice that are transgenic (tg) for an OVA-
specific TCR (Fig. 6, C and D; Barnden et al., 1998), and 
NFATc1/ c2/ double KO B cells displayed even less 
stimulatory activity (Fig. S6).
Figure 6.  Ablation of NFATc1 in B cells impairs their T cell help. (A and B) MLC. In A, 5 × 104 B cells from C57/BL6 WT or Cd23-cre x Nfatc1flx/flx 
mice were incubated with 5 × 104 CFSE-labeled CD4+ T cells from a BALB/c WT mouse. After 3 d, proliferation of T cells was measured. In B, B and T cells 
were cultured as in A and IL-2 secretion was measured by ELISA. In A, one typical assay out of three is shown; in B mean values of two assays are com-
piled. (C and D) Splenic B cells from WT and Cd23-cre x Nfatc1flx/flx mice were treated overnight with 10 µg/ml -IgM and 1 µM (C) or 10 µM OVA323-339 
peptide (D) followed by incubation with CFSE-stained 5 × 104 T cells from an OTII tg mouse (Barnden et al., 1998) for 3 d. In C, one typical assay out of 
three is shown. In D, mean values of three experiments are presented.JEM VOL. 208, April 11, 2011 
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adding -IL-10. By adding -IL-10 to T cell co-cultures, in 
part the suppressive effect of NFATc1/ B cells could be re-
lieved (Fig. 7 E), suggesting that an increase in IL-10 produc-
tion by NFATc1/ splenic B cells contributes to suppression 
of T cell proliferation in vitro.
These in vitro findings prompted us to investigate whether 
NFATc1/ B cells affect the clinical course of mouse EAE 
(Hur et al., 2007), a mouse model for human multiple sclerosis, 
B cells suppressed the IFN- production of T cells, whereas 
WT B cells did not or only slightly affected T cell IFN- ex-
pression. This suppressive effect of NFATc1/ B cells was 
markedly reduced by adding the IL-10–specific antibody 
JES5-2A5, which relieved IL-10–mediated inhibition of cyto-
kine production of T cells by B cells (Lampropoulou et al., 
2008). A very strong suppressive effect on IFN- production 
was exerted by recombinant IL-10 that could be relieved by 
Figure 7.  NFATc1 ablation leads to an increase in IL-10 production and amelioration of the clinical course of EAE. (A) Increased 
CD19+CD5+CD1dhigh B cell number in spleen freshly prepared from Cd23-cre X Nfatcflx/flx mice, compared with WT mice. Six individual mice were investi-
gated, and mean values are shown. (B) IL-10 production of unstimulated CD5+CD1dhigh NFATc1/ B cells or cells treated with -IgM or LPS (10 µg/ml 
each) for 24 h and with T+I for the last 8 h. Cells were stained with antibodies directed against CD1d and CD5, and against IL-10 for intracellular flow 
cytometry. Shown are the results of one (out of five) typical experiment of IL-10 stains of CD5+CD1dhigh B cells. (C) Increase in IL-10–producing 
CD138+CD19+ plasmablasts after 3 d in culture with LPS (and T+I for the last 6 h) in preparations of splenocytes from mice bearing Cd23-cre x Nfatc1flx/flx 
B cells. One typical assay out of three is shown. (D) IL-10 production by unstimulated WT and NFATc1/ splenic B cells and cells stimulated by -IgM or 
LPS for 72 h in culture. IL-10 was measured in ELISA, and mean values of three assays are shown. (E) MLC. Decreased IFN- production by CD4+ T cells 
incubated for 48 h in the presence of 0.5 µg/ml -CD3 and, during the last 6 h, with T+I, without B cells or with unstimulated B cells or B cells prestimu-
lated by -IgM or LPS for 24 h from WT or mb1-cre x Nfatc1flx/flx mice. As indicated, 5 ng/ml recombinant IL-10 and/or 1 µg/ml of IL-10–specific antibody 
JES5-2A5 (Lampropoulou et al., 2008) were added to the cultures. One typical set out of three assays is shown. (F) EAE. By injection of MOG35-55 peptide in 
complete Freund’s adjuvant, and pertussis toxin at day 2 (Pierau et al., 2009), EAE was induced in mb1-cre x Nfatc1flx/flx and WT mice as indicated. The data 
show the mean clinical score + SEM from 3 independent experiments, with n = 9 (WT) and n = 14 (mb1-cre x Nfatc1flx/flx) mice.834 NFATc1 controls mouse B cell fate | Bhattacharyya et al.
those mice defective in individual components of BCR sig-
naling. However, collectively, the phenotype of NFATc1/ 
B cells indicates that the induction of NFATc1 represents an 
important molecular event of BCR signaling that transmits 
antigenic signals from the BCR to NFATc1 and, finally, to 
the numerous NFATc1 target genes that control the prolifer-
ation, AICD, cytokine production and TI-type II antigen–
mediated Ig switch of splenic B cells.
The diminished release of Ca2+ from intracellular stores 
and the decrease in Ca2+ influx in NFATc1/ B cells suggest 
NFATc1 as a key molecule in adjusting the levels of free   
intracellular Ca2+ in B cells. Although it is currently unknown 
how NFATc1 controls these signaling events, the expression 
(or activation) of molecules involved in early BCR signaling 
controlling Ca2+ release from endoplasmic stores seem to be 
under NFATc1 control. One prominent candidate gene is the 
Cd22 gene, whose expression is enhanced in NFATc1/  
B cells. Inactivation of the Cd22 gene, on the other hand, re-
sulted in an increase of NFATc1/A levels in unstimulated 
B cells and B cells treated with LPS (Fig. S4 F). CD22 affects 
BCR signals by recruiting the tyrosine phosphatase SHP-1 
upon phosphorylation of its multiple motifs, and it is likely 
that SHP-1 affects the phosphorylation of members of BCR 
cascade, such as of Btk, SLP-65, or PLC-2 that control Ca2+ 
release through activating IP3 receptors (Nitschke, 2009).
It is currently unknown whether CD22 is the only (or 
major) target through which NFATc1 affects Ca2+ flux. The 
expression of human SERCA3 (ATP2A3) gene in endothe-
lial cells and mouse IP3R1 (Itpr1) gene in hippocampal neu-
rons have been described to be under NFAT control (Graef 
et al., 1999; Hadri et al., 2006), but studies on IP3R1 expres-
sion in T cells (Nagaleekar et al., 2008) did not reveal a positive 
effect of NFATs on IP3R1 expression in these cells. Likewise, 
the expression of PLC-2, Btk, and SLP-65 appeared to be 
quite normal in NFATc1/ B cells (unpublished data). How-
ever, large proteins such as IP3R1 and PLC-2 are expressed 
from very complex genes that, like the Rcan1 and Nfatc1 genes, 
might be under the control of multiple promoters and/or 
poly A sites and alternately spliced. It remains to be shown 
whether this is true for other molecules of BCR signaling.
Prominent upstream NFAT targets of Ca2+/Cn cascade 
are Rcan1, the gene encoding the Cn inhibitor calcipression/
DSCR1, and the Ppp3cb gene expressing CnA , the  form 
of catalytic subunit A of Cn in lymphocytes. For both the 
Rcan1-4 and Ppp3cb promoters, arrays of NFAT motifs have 
been described, and the binding of NFAT factors to these 
promoters has been reported for nonlymphoid cells (Rothermel 
et al., 2003; Oka et al., 2005). Our data indicate that in B cells 
Rcan1, CnA , and NFATc1 form a regulatory network 
(Fig. S5 A) that helps to fine tune the proper expression of 
NFATc1, in particular of NFATc1/A, and the activation of 
further NFATc factors during immune responses.
NFATc1 expression supports BCR-mediated prolifera-
tion and suppresses AICD of primary B cells (Fig. 2), e.g., in 
the early clonal expansion phase of an immune response. 
Although there are several studies on a direct NFAT-mediated 
which is strongly affected by IL-10 (Fillatreau et al., 2002; 
Bouaziz et al., 2008). By inducing adjuvant-driven EAE (Pierau 
et al., 2009) in mb1-cre x NFATc1flx/flx and WT mice, we ob-
served that NFATc1 ablation in BM B cells resulted in a 
much milder EAE than in control mice. Whereas in control 
mice the onset of EAE was detected 7–8 d after MOG35-55 
peptide injection reaching EAE scores of 2–2.5 at day 20, for 
mb1-cre x Nfatc1flx/flx mice first EAE signs were obvious at day 
11  upon  MOG35-55  injection,  reaching  scores  of  0.5–1.0 
(Fig. 7 F). This shows that the expression of NFATc1 in B cells 
enhances the severity of EAE.
DISCUSSION
The results of this study show that ablation of NFATc1 in 
committed BM pro-B cells or in splenic B cells exerts a rela-
tive mild effect on the overall differentiation of peripheral 
B cells. Peritoneal CD5+ B1a cells are the notable exception 
because their generation is strictly dependent on NFATc1 
expression (Fig. S2, E and F; Berland and Wortis, 2002, 2003). 
However, although NFATc1 activity seems to play a minor 
role in the development of B cells in BM and periphery, it is 
of crucial importance for the fate and function of B cells 
upon BCR triggering. Our data show that NFATc1 controls 
(a) the proliferation and AICD of splenic B cells (and plasma-
blasts) upon BCR stimulation, (b) the Ig class switch to IgG3 
by the TI-type II antigen NP-Ficoll and the formation of 
IgG3+ plasmablasts in vitro, (c) the IL-10 production of 
CD1dhighCD5+ B cells that suppressed the IFN- production 
by and proliferation of co-cultivated CD4+ T cells, and (d) the 
clinical course of MOG-peptide/adjuvant-driven EAE, a 
mouse model of human multiple sclerosis. Because NFATc1 
ablation led to a marked decrease in the release of Ca2+ from 
endoplasmic stores, Ca2+ influx and Cn activity as well as in 
distinct changes in expression of genes that affect (or are af-
fected by) Ca2+ levels, one may conclude that NFATc1 con-
trols Ca2+ flux and Cn activity in peripheral B cells.
NFATc1/ B cells share several characteristics with B cells 
from mouse models in that individual components of BCR 
signaling cascade have been inactivated. Such as with mice 
deficient for Btk (Kerner et al., 1995; Khan et al., 1995), 
PLC-2 (Hashimoto et al., 2000; Wang et al., 2000), and SLP-
65/BLNK (Jumaa et al., 1999; Pappu et al., 1999; Xu et al., 
2000), and with IgY204F/Y204F ‘knock in’ (k.i.) mice (Patterson   
et al., 2006). Similar to mb1-cre x Nfatc1flx/flx mice, these mice 
have a severe block in the generation of B1a cells and in Ig 
class switch upon immunization with TI-type II, but not TD 
antigens, and their B cells are characterized by a marked di-
minished Ca2+ flux and BCR-mediated proliferation. How-
ever, contrary to B cell development in mb1-cre x Nfatc1flx/flx 
mice, SLP-65/ mice show a defect at the pre–B cell stage 
(of CD43+BP1+IgM- cells) in BM and, therefore, a drastic re-
duction in number of peripheral B cells (Jumaa et al., 1999). 
Unlike B cells from mb1-cre x Nfatc1flx/flx and SLP-65/ mice, 
IgY204F/Y204F k.i. B cells did not show an impaired survival in 
vitro (Patterson et al., 2006). These observations indicate that 
NFATc1/ B cells share several, but not all properties with JEM VOL. 208, April 11, 2011 
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of the mouse Nfatc1 gene with loxP sites (to be described in detail elsewhere). 
All of the following gene-deficient mice were published previously: Btk 
(Khan et al., 1995); SLP-65 (Jumaa et al., 1999); IL-10 (Kühn et al., 1993); 
CD22 (Nitschke et al., 1997); Light (Scheu et al., 2002); and PD-1 (Nishimura 
et al., 1999). Transgenic Nfatc1-Egfp reporter mice were created upon inser-
tion of a Egfp cDNA into exon 3 of mouse Nfatc1 locus cloned in a BAC 
vector spanning 210 kb Nfatc1 DNA. Details of those BAC-tg mice will be 
published elsewhere. Animal experiments were performed according to proj-
ect licenses (55.2–2531.01-53/10B), which are approved and controlled by the 
Regierung von Unterfranken, Würzburg. In most of experiments, 6–8-wk-old 
mice were used. Naive splenic B cells were isolated using Miltenyi Biotec cell 
isolation kit to a purity of 95–98% as determined by flow cytometry. 0.5–1 × 
106 cells were cultured in 200 µl X-vivo 15 medium (Lonza) and stimulated 
with 10 µg/ml LPS (Sigma-Aldrich), 1–10 µg/ml -IgM (F(ab)2 fragment 
goat anti–mouse IgM; Jackson ImmunoResearch Laboratories), 1 or 2 µg/ml 
-CD40 (R&D Systems) or TPA and ionomycin as specified in the figure 
legends. Cell cultures were supplemented with CaCl2 as specified, and/or 
with the Cn inhibitors cyclosporin A and FK506, or the NFAT inhibitor 
11R-Vivit (EMD). Because of its better solubility and cellular penetration, 
11R-Vivit was dissolved in DMSO and used in concentrations between 0.1 
and 10 µM. Because DMSO itself interfered with B cell survival, the effect of 
DMSO on B cells was tested in parallel assays.
Naive CD4+ T cells were isolated using a CD4+ T cell isolation kit 
(Miltenyi Biotec), stained with CFSE and incubated with B cells that were 
preactivated overnight by incubation with 10 µg/ml -IgM. IL-2 secretion 
of T cells was measured with a Ready-Set-Go ELISA kit (eBioscience).
EAE induction. Mice were immunized with 200 µg of myelin oligoden-
drocyte (MOG35-55) peptide in CFA (Sigma-Aldrich) containing 800 mg of 
heat-killed Mycobacterium tuberculosis (Difco) as described previously in detail 
(Pierau et al., 2009). Animal experiments were approved by the state authorities 
of the Land Sachsen-Anhalt. Mice with a clinical score >2.5 were killed accord-
ing to the animal statutes. The MOG peptide was provided by D. Rheinhold 
(Institute of Medical and Clinical Immunology, Magdeburg, Germany).
Gene expression analysis and statistical evaluation. B cells from WT 
and mb1-cre x Nfatc1flx/flx mice were left unstimulated or stimulated with 
10 µg/ml -IgM for 3, 8, and 16 h, respectively. Their RNA was isolated from 
frozen cells using the TRIzol reagent (Invitrogen). Gene expression analysis 
was performed in three biological replications using the mouse whole genome 
430 2.0 gene expression arrays from Affymetrix. The data were normalized to 
500  arbitrary  units  (MAS5)  using  the  Gene  Chip  Operating  Software 
(GCOS) from Affymetrix. For statistical analysis absent signals were floored 
to a common baseline (50 U) and expression values were log2 transformed.
To compare the gene expression profiles between the WT and Nfatc1/ 
phenotypes for any given time point (3, 8, and 16 h after -IgM stimulation), 
data were time zero transformed and sorted for differential expression. Genes 
that showed at least a twofold difference in expression in all three replicates 
were determined by overlap analysis using Access. Gene set enrichment analysis 
(GSEA;  http://www.broad.mit.edu/gsea)  was  performed  as  described 
(Subramanian et al., 2005) using 81 lymphoma associated gene signatures 
published previously (Shaffer et al., 2001) from the signature database of the 
Staudt laboratory http://lymphochip.nih.gov/signaturedb/ and 1.687 curated 
gene sets (c2) from the Molecular Signatures Database (MSigDB; Subramanian 
et al., 2005). Because both phenotypes that were compared in this approach 
consisted of less than seven samples, “gene set” was chosen as permutation type 
in the settings of the GSEA software, as recommended by the GSEA team.
The signatures and gene sets were regarded as significantly enriched when 
the nominal P value and the tail area FDR (tail area false discovery rate) were 
less than 0.05 and 0.25, respectively. A selective leading edge analysis was per-
formed using significantly enriched gene sets to extract the genes that ac-
count for the enrichment score.
For visualization of the data the Cluster and TreeView software packages 
provided by M. Eisen (http://rana.lbl.gov/EisenSoftware.htm; University of 
California, Berkeley, Berkeley, CA) were used.
regulation of cell cycle mediators in T cells (Baksh et al., 2002; 
Caetano et al., 2002; Carvalho et al., 2007), in our microarray 
studies among the numerous cyclin, cdk, or cell cycle inhibitor 
genes we detected only the Ccnb1 gene, encoding Cyclin B1, 
as a putative NFATc1 target gene in B cells (Table S1). This 
finding led us to conclude that in B cells, NFATc1 enhances 
numerous genes controlling cell cycle at moderate levels, and 
gene set enrichment analyses (Table I) support this view. One 
exception might be the Bcl2 gene (Table S2) that, in addition 
to its role in apoptosis, was described to retard cell cycle entry 
(Vairo et al., 2000). However, the detection of proapoptotic 
factors FasL, PD-1, and Light molecules as direct NFATc1 
target and own experimental data (unpublished data) suggest 
that at very high concentrations NFATc1/A could also act 
in a proapoptotic manner, killing the majority of amplified 
lymphocytes at the end of an immune response. But further 
experiments using more appropriate mouse models are nec-
essary to substantiate this hypothesis.
The increase in CD1dhighCD5+ B cells producing IL-10 
suggests that NFATc1 affects the regulatory capacity of B cells. 
The Il10ra gene belongs to the 37 genes whose expression 
was markedly increased in NFATc1/ B cells (Table S2), and 
in 2 out of 3 microarray assays a similar increase was detected 
for the Il10 gene (unpublished data). This implies that the in-
duction of NFATc1 in B cells suppresses, either directly or indi-
rectly, IL-10 production. This conclusion is supported by the 
-IgM–mediated decrease in IL-10 synthesis of CD1dhighCD5+ 
B cells upon BCR triggering and NFATc1 induction, and 
suggests that the increase in IL-10–producing B cells contrib-
utes to the clinical course of EAE in mb1-cre x NFATc1flx/flx 
mice. It has previously been shown that B cells play a key role 
in recovery from EAE by the secretion of IL-10 (Fillatreau 
et al., 2002). Along with studies on a regulatory role of B cells 
in the generation of EAE (Yanaba et al., 2008; Pöllinger et al., 
2009), our findings lend support to this observation, but also 
suggest that an impaired antigen-presentation by NFATc1/ 
B cells might ameliorate EAE symptoms (Fig. 6, C and D).   
In  addition  to  IL-10,  other  candidates  that  affect  EAE   
are IFN- and osteopontin/Spp1 (Hur et al., 2007), which 
are both encoded by top ten NFATc1 target genes (Fig. 2 
and Table S1).
Collectively, the data of our study show that the induction 
of NFATc1 plays an important role in the activation and func-
tion of splenic B cells upon BCR stimulation. Missing or in-
complete NFATc1/A induction appears to be one reason 
for the generation of B cell unresponsiveness whereas uncon-
trolled NFATc1/A expression could lead to unbalanced 
immune reactions and autoimmune diseases. Experiments are 
in progress to elaborate more details of this view.
MATERIALS AND METHODS
Mice, cell isolation and cell cultures. The B cell stage-specific cre lines 
mb1 (Cd79a)-cre (Hobeika et al., 2006), Cd23-cre, and Aicda-cre (Kwon et al., 
2008) have been described previously. Mice bearing a conditional allele of Nfatc1 
(Nfatc1flx; also designated as Nfat2flx) were generated by K. Mark Ansel, M.R. 
Müller, and A. Rao (Harvard Medical School, Boston, MA) by flanking exon 3 836 NFATc1 controls mouse B cell fate | Bhattacharyya et al.
Immunohistochemistry. For antigen localization (Fig. 5), 150 µg TNP- 
Ficoll was injected into the tail vein of mice. 60 min later, B cells were pre-
pared for flow cytometry from one part of the spleen, and the other part was 
used for histological examination. Cryosections were stained with biotin-
conjugated hamster -TNP-Ficoll IgG (BD), -CD169/MOMA-1 (Serotec), 
-IgD, or -IgM (SouthernBiotech).
For nuclear localization of NFATc2 (Fig. 3 F), splenic B cells stimulated 
for 24 h by 10 µg/ml -IgM and 5 µg/ml -CD40 and stimulated by T+I 
for 30 min were harvested by cytospin, dried overnight, fixed in acetone, and 
stained with antibodies directed against NFATc2 (BD or Santa Cruz Bio-
technology). Nuclear localization of NFATc2 in 100 cells from three indi-
vidual experiments was determined by confocal microscopy.
Calcium measurements. 5 × 106 of freshly prepared murine splenic B cells 
were incubated in 700 µl X-vivo medium or RPMI 1640 (Invitrogen) con-
taining 5% FCS (PAN), 1 µM Indo-1-AM (Invitrogen), and 0.015% Pluronic 
F127 (Invitrogen) at 30°C for 25 min. The cell suspension was then diluted 
with 700 µl medium containing 10% FCS and incubated at 37°C for another 
10 min. The cells were washed twice with Krebs-Ringer solution containing 
10 mM Hepes, pH 7.0, 140 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, 10 mM glucose, and 0.5 mM EGTA and diluted to a concentration 
of 107 cells per ml. For measurement, the cells were diluted 1:10 in Krebs-
Ringer solution and a baseline was recorded for 60 s. Ca2+ movement was 
assessed after stimulation of the cells with -IgM (Jackson ImmunoResearch 
Laboratories), followed by the addition of Ca2+ in denoted concentrations after 
2 min of recording. Increases in free intracellular Ca2+ were measured in real-
time on a LSR II (BD). Raw data files were transferred to FlowJo software 
and are presented as a median and in comparative overlay analyses.
Determination of Cn activity and cellular CnA levels. Cn activity of 
freshly prepared naive splenic B cells was determined using BIOMOL’s non-
radioactive Cn kit according to the manufacturer’s instructions. In brief, 3 × 107 
splenic B cells were lysed in 50 µl of lysis buffer (+ protease inhibitors) by pi-
petting and vortexing, followed by high speed centrifugation for 45 min at 
4°C in an Eppendorf centrifuge. For removing free phosphate, supernatants 
were passed through a desalting spin column, stored on ice, or quick-frozen 
in liquid nitrogen before storage at 70°C. Aliquots of supernatant corre-
sponding to 3 × 106 of B cells were tested in 50-µl assays, containing the 
RII phosphopeptide Cn substrate. The release of free phosphate was deter-
mined in a Malachite green assay. Incubations of parallel assays containing either 
no substrate, or 10 mM EGTA and EGTA+okadaic acid indicated the speci-
ficity of Cn reaction. In immunoblots, a CnA /-specific antibody (BD) 
was used to determine CnA levels (Fig. 3 E).
ChIP  assays. ChIP assays were performed according to a previously 
published protocol (Soutoglou and Talianidis, 2002) and slightly modified. 
In brief, the chromatin of 0.5–1 × 108 splenocytes was cross-linked using 1% 
formaldehyde, and the reaction was quenched with 125 mM glycine. Nuclei 
were isolated and treated with DNase I, sonicated, and, after preclearing with 
protein A–Sepharose that was blocked with salmon sperm DNA, protein–
DNA complexes were immunoprecipitated using an NFATc1 mAb (BD), or 
an unrelated GST antibody as control. After washing, elution, and reversion 
of cross-links, DNA was isolated by phenol/chloroform and used in PCR 
reactions that were performed with the following primers amplifying the 
promoters  of  the  following  genes:  Il2,  forward  5-CCTGTGTGCAATT-
AGCTCA-3 and reverse 5-CTCTTCTGATGACTCTCTGGA-3; Fasl, 
forward 5-ACTTGCTGAGTTGGACCTCA-3 and reverse 5-GTAAT-
TCATGGGCTGCTGCA-3;  Pdcd1,  forward  5-CAGGCACAGAACGTT-
CAGGAA-3 and reverse 5-AACAGGAGTTAGGGATCACA-3; Rcan1, 
forward 5-GCGGCATAGTTCCCACTGGTA-3 and reverse 5-GAGT-
GCTGGGCTTTTCATCCA-3; Spp1, forward 5-CACACTCTCCATG-
CCAGAGCA-3  and  reverse  5-CACAGAGGCCTCTGCTTGTCA-3; 
Tnfsf14, forward 5-TGTCCGTCTGTCCATCCACCA-3 and reverse   
5-GGTGCAAGATGCTTGCATGGA-3; Ppp3ca, forward 5-TTTTCTTCA-
GGGTGCCAGTC-3 and reverse 5-CAGTCTGTTCCCATCCACCT-3;   
Western blotting. Western blots were performed by separation of whole 
protein extracts on PAGE-SDS gels followed by immunodetection of NFATc1 
using the 7A6 mAb (obtained from BD or Santa Cruz Biotechnology) or 
polyclonal antibodies (pAB) specific for NFATc1 or NFATc2 (ImmunoGlobe). 
For detecting NFATc1/A (Fig. 1 B), a pAb raised against the NFATc1   
-peptide (ImmunoGlobe) was used. As loading control, filters were stained 
by Ponceau red. Signals were developed by chemiluminescence detection   
using Super Signal (Thermo Fisher Scientific).
Apoptosis assays and flow cytometric analysis. Apoptosis assays were 
performed by staining with propidium iodide (PI, 125 µg/ml) and Annexin 
V-FITC (BD), incubated for 15 min at 37°C and analyzed on FACSCalibur 
using CellQuest software (BD) and FlowJo (Tree Star, Inc.). Electronic com-
pensation of the instrument was done to exclude overlapping emission spec-
tra. In total, 10,000 events were acquired, the cells were gated, and dual 
parameter dot plots of FL1-H (x-axis; FITC-fluorescence) versus FL2-H 
(y-axis; PI-fluorescence) were gated in logarithmic fluorescence intensity. For 
IL-10 detection in specific B cell subset, nonstimulated cells or cells stimu-
lated with -IgM or LPS were treated by T+I and GolgiPlug for the last 8 h, 
blocked with mouse Fc receptor specific mAb (BD) and stained with CD5 
PE and CD1d FITC mouse-specific antibodies (BD). Cells were fixed and 
permeabilized using the eBioscience fixing and permeabilizing kit according 
to manufacturer’s instructions. Next, cells were stained with anti–mouse IL-10 
APC antibody (eBioscience). Unstimulated cells and isotype controls were 
also used in flow cytometric analysis.
For the determination of cell cycle phase distribution of nuclear DNA, 
cells were first fixed in 100% methanol, permeabilized, and nuclear DNA   
was labeled with PI (125 µg/ml) after RNase (10 µl from 2 mg/ml stock) treat-
ment. Cell-cycle phase distribution of nuclear DNA was determined on a 
FACSCalibur using CellQuest software, fluorescence (FL2-A) detector equipped 
with a 488-nm Argon laser light source and a 623-nm band pass filter (linear 
scale).  In  total,  10,000  events  were  acquired  for  analysis.  CellQuest  and 
FlowJo statistics was used to quantify the data at different phases of the cell 
cycle. Histogram display of FL2-A (x axis, PI-fluorescence) versus counts   
(y axis) has been displayed in Fig. S3 C.
Immunizations and ELISAs. NP-Ficoll (10 µg/mouse in PBS) or NP-KLH 
(100 µg/mouse, Alum precipitated) was i.p. injected into age-matched mice. 
Levels of NP-specific antibodies were determined by ELISA with 10 µg/ml   
NP-BSA coated MaxiSorp plates (Nunc). A sample of pooled sera from days 
7 and 21 was used as standard and included on every ELISA plate. Total Ig   
titers from naive mice were determined by ELISA on PolySorp plates (Nunc) 
coated with isotype-specific antibodies and monoclonal antibody, and iso-
type antibodies served as standards (SouthernBiotech). Serum samples were 
applied as serial dilutions, and their concentration was quantified against   
the standard curve. Isotype-specific antibodies coupled to alkaline phospha-
tase were used for detection.
In vitro class-switching assays. 106 splenocytes were cultured in 1 ml 
X-vivo medium without or with LPS (10 µg/ml) or with LPS + IL-4   
(10 ng/ml) for 2 d, followed by RNA extraction with TRIzol and cDNA 
synthesis using the iScript cDNA Synthesis kit (Bio-Rad Laboratories). PCR 
reactions were performed with the primers for the detection of IgG3 and IgG1 
circular transcript as described (Kinoshita et al., 2001). 2.5 × 105 splenocytes 
were cultured in 1 ml X-vivo medium and stimulated without or with LPS 
for 6 d. Supernatants were collected and subjected to ELISA. Unlabeled goat 
anti–mouse IgM and IgG3 were used to coat ELISA plates, mouse IgM and 
IgG3 (0.1 mg/ml each) were used as standards, and alkaline phosphatase–
coupled, isotype-specific antibodies were used for detection. Splenocytes stimu-
lated with LPS for 3 d were stained with antibodies directed against CD19, 
CD138, and IgG1 and/or IgG3 for the detection of Ig class switch.
In vitro IL-10 secretion assay. 4 × 104 cells were incubated in 200 µl   
X-vivo medium with or without -IgM or LPS for 72 h, and supernatants 
were collected. ELISA was performed using a mouse IL-10 ELISA kit (eBio-
science) according to the manufacturer’s instructions.JEM VOL. 208, April 11, 2011 
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Ppp3cb,  forward  5-GCTTAGACTTTTCCAGCTGA-3  and  reverse   
5-GAGGCTACTACAGAAACGGAA-3.
RT-PCR assays. RNA was purified using TRIzol reagent (Invitrogen) and 
first strand synthesis was performed with 1 µg of RNA according to manufac-
turer’s protocol (Fermentas). For PCR reactions, the following primers were 
used: Cd22, forward 5-TCCCAGACTTTCCCCTCCCTA-3 and reverse 
5-CAACCACTTTTACCCACTGA-3; Nfatc2, forward 5-GGGTTCG-
GTGAGTGACAGTT-3 and reverse 5-CTCCTTGGCTGTTTGGG-
ATA-3;  Nfatc3,  forward  5-CACGCCGATGACTACTGCAAACTG-3 
and reverse 5-CCTTGGAGCTGAAATGATGGTGAC-3.
Statistical analysis. All statistical analysis was performed using SPSS soft-
ware. The Mann-Whitney test was used to evaluate the significance of differ-
ences in Cn measurements, for other results the unpaired Student’s t test was 
used. Differences with P values of 0.05 and less are considered as significant. 
*, P < 0.05; **, P < 0.005, and ***, P < 0.001. If not stated otherwise, mean 
values from three assays are shown, or one representative experiment is shown 
from three similar assays.
Accession nos. The GEO accession no. for microarray data is GSE21063.
Online supplemental material. Fig. S1 shows immunoblots indicating the 
induction of NFATc1 upon -CD40 and T+I stimulation and the loss of 
NFATc1 induction in splenic B cells from mb1-cre and Cd23-cre x Nfatc1flx/flx 
mice. Fig. S2 shows flow cytometric data on the role of NFATc1 on B cell 
development in BM, LN, spleen, and peritoneum. Fig. S3 demonstrates the 
effect of NFATc1 ablation on the proliferation and survival of splenic B cells. 
In Fig. S4, data are compiled on the effect of novel Cn inhibitor NCI3 on prolif-
eration of splenic B cells, of the NFAT inhibitor VIVIT on proliferation and 
apoptosis of splenic B cells, of NFATc1 ablation on Ca2+ flux, and on CD22 
ablation on NFATc1 induction in splenic B cells. Fig. S5 shows a model on the 
control of Cn-NFAT network by NFATc1; serum Ig levels of nonimmunized 
WT, mb1-cre, Cd23-cre, and Aicda-cre x Nfatc1flx/flx mice; serum Ig levels of WT 
and Cd23-cre x Nfatc1flx/flx mice upon immunization with NP-KLH; and the 
affinity of IgG1 antibody generated upon immunization with anti-NP4 or 
anti-NP16 KLH. Fig. S6 shows the effect of NFATc1 and NFATc2 ablation 
on the capacity of B cells to stimulate T cells to produce IL-2 and to proliferate. 
In Table S1, genes are compiled that were twofold stronger expressed in WT 
than NFATc1/ splenic B cells. In Table S2, genes are compiled that were two-
fold stronger expressed in NFATc1/ splenic B cells. In Table S3, a leading 
edge analysis of pathways/gene sets is shown that were significantly enriched 
in splenic B cells from WT mice compared with those from mb1-cre x Nfatc1flx/flx 
mice after 16 h stimulation with -IgM. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20100945/DC1.
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